Single cell technology is the basis of our discovery-phase research. After pathological determination of acute cellular rejection, lung tissue from transbronchial lung biopsies are dissociated into single cells and profiled using 10X Genomics Chromium 5’v2 chemistry. This technology, along with a robust bioinformatic pipeline, is enabling unprecedented molecular insights into the mechanisms of acute cellular rejection of lung allografts that result in long-standing dysfunction.
Single cell technology and flow cytometry are the basis of our discovery-phase research. Bronchoalveolar lavage fluid and blood are collected from patients with CF. Cells from these samples undergo flow cytometry and are dissociated into single cells and profiled using 10X Genomics Chromium 5’v2 chemistry. This technology, along with a robust bioinformatic pipeline, is enabling unprecedented molecular insights into the mechanisms of biogeographic immunologic differences in the CF lung.